RGLS Share Price | Regulus Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Regulus Therapeutics, Inc.?

Market Cap: As of Jun 18, Regulus Therapeutics, Inc. has a market capitalization of 567.72 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Regulus Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -47.52 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 76.41 million and total assets of 84.18 million.

Q: What does Regulus Therapeutics, Inc. do?

Overview: Regulus Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market cap: USD 567.72 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.94 Return on Equity: -68.85% Price to Book: 8.22Contact Details: Address: 10628 Science Center Dr Ste 225, SAN DIEGO CA: 92121-1124 Tel: 1 858 2026300 Website: http://www.regulusrx.com/

Q: Is Regulus Therapeutics, Inc. overvalued or undervalued?

As of 11 March 2022, the valuation grade for Regulus Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 8.24 and an EV to Capital Employed ratio of 120.55, which suggests that the market is pricing the company at a premium despite its poor financial performance. Additionally, the negative ROCE of -1237.25% and ROE of -68.85% further highlight the challenges the company faces.In comparison to its peers, Regulus Therapeutics, Inc. has a less favorable EV to EBITDA ratio of -9.81, while BeyondSpring, Inc. and Aligos Therapeutics, Inc. have ratios of -7.9578 and 0.6671, respectively, indicating that Regulus is underperforming relative to these competitors. Despite its recent strong returns, with a year-to-date stock return of 416.46% compared to the S&P 500's 12.22%, the valuation metrics suggest that the stock is not justified at its current price level.

Q: Is Regulus Therapeutics, Inc. technically bullish or bearish?

As of 27 May 2025, the technical trend for Regulus Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the MACD (both weekly and monthly), Bollinger Bands (weekly and monthly), KST (weekly and monthly), and moving averages (daily). However, the RSI indicates bearish momentum on both the weekly and monthly time frames, and Dow Theory shows a bearish signal on the weekly chart with no trend on the monthly.In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 416.46% compared to the S&P 500's 12.22%, and over the past year, it has returned 300.0% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Mar 2025)

FII

2.69%

Held by 17 FIIs

DII

48.62%

Held by 41 DIIs

Promoter

13.99%

How big is Regulus Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Regulus Therapeutics, Inc. has a market capitalization of 567.72 million, with net sales of 0.00 million and a net profit of -47.52 million over the last four quarters. The company reported shareholder's funds of 76.41 million and total assets of 84.18 million as of Dec 24.

View full answer

What does Regulus Therapeutics, Inc. do?

22-Jun-2025

Regulus Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs that target microRNAs for various diseases. It has a market cap of approximately $567.72 million and reported a net profit loss of $10 million in March 2025.

View full answer

Who are in the management team of Regulus Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Regulus Therapeutics, Inc. includes Dr. Stelios Papadopoulos (Independent Chairman), Mr. Joseph Hagan (President and CEO), and several Independent Directors: Dr. David Baltimore, Ms. Kathryn Collier, Mr. Jake Nunn, Dr. William Rastetter, and Dr. Hugh Rosen. This team provides executive leadership and governance for the company.

View full answer

Is Regulus Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of March 11, 2022, Regulus Therapeutics, Inc. is overvalued with a valuation grade of "does not qualify," indicated by poor financial metrics such as a Price to Book Value of 8.24, negative ROCE of -1237.25%, and underperformance compared to peers, despite a year-to-date stock return of 416.46%.

View full answer

Is Regulus Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of May 27, 2025, Regulus Therapeutics, Inc. shows a bullish trend supported by various indicators, despite bearish momentum in the RSI and Dow Theory, and has significantly outperformed the S&P 500 with a year-to-date return of 416.46% compared to 12.22%.

View full answer

Compare Regulus Therapeutics, Inc. with Similar Stocks

Matinas BioPharma Holdings, Inc.Lumos Pharma, Inc.Cellectar Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 534 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

85.78%

Debt Equity

-0.94

Return on Equity

-68.85%

Price to Book

7.74

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

513.53%

6 Months

397.56%

1 Year

233.06%

2 Years

504.44%

3 Years

217.63%

4 Years

-22.29%

5 Years

-8.97%

Regulus Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.23%

EBIT Growth (5y)

-191.35%

EBIT to Interest (avg)

-30.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.94

Sales to Capital Employed (avg)

0.15

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

8.24

EV to EBIT

-9.74

EV to EBITDA

-9.81

EV to Capital Employed

120.55

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1237.25%

ROE (Latest)

-68.85%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Bearish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 19 Schemes (34.7%)

Foreign Institutions

Held by 17 Foreign Institutions (2.69%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -12.94% vs -19.72% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.50",
          "val2": "-8.70",
          "chgp": "-20.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.60",
          "val2": "-8.50",
          "chgp": "-12.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -54.67% vs -6.01% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.70",
          "val2": "-30.90",
          "chgp": "-60.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.60",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-46.40",
          "val2": "-30.00",
          "chgp": "-54.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.50

-8.70

-20.69%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-9.60

-8.50

-12.94%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -12.94% vs -19.72% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-49.70

-30.90

-60.84%

Interest

0.20

0.60

-66.67%

Exceptional Items

0.00

Consolidate Net Profit

-46.40

-30.00

-54.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -54.67% vs -6.01% in Dec 2023

All Annual Results

Company CV

About Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Company Coordinates

Company Details

10628 Science Center Dr Ste 225 , SAN DIEGO CA : 92121-1124

Tel: 1 858 2026300

http://www.regulusrx.com/

Registrar Details

Regulus Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Regulus Therapeutics, Inc.?

Watch in Real-Time

What does Regulus Therapeutics, Inc. do?

Who are in the management team of Regulus Therapeutics, Inc.?

Is Regulus Therapeutics, Inc. overvalued or undervalued?

Is Regulus Therapeutics, Inc. technically bullish or bearish?

Compare Regulus Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Regulus Therapeutics, Inc.

Company Coordinates